Skip to main content
. 2021 Aug 10;133(17-18):931–941. doi: 10.1007/s00508-021-01922-y

Fig. 3.

Fig. 3

a Anti-spike protein IgG in initially seronegative participants who received both vaccinations in the different study groups, and human convalescent sera (HCS) samples (Hos hospitalized, Out outpatients) measured by ELISA. Bars show median values per group at each study timepoint (whiskers show IQR) and individual GMT values for each sample shown as diamonds. Numbers show median values at day 43 for each group, and in the convalescent sera. b Anti-RBD IgG in initially seronegative participants who received both vaccinations in the different study groups and human convalescent sera (HCS) samples (Hos hospitalized, Out outpatients) measured by ELISA. Bars show median values per group at each study timepoint (whiskers show IQR) and individual GMT values for each sample shown as diamonds. Numbers show median values at day 43 for each group, and in the convalescent sera. c Anti-SARS-CoV‑2 virus neutralizing titers in initially seronegative participants who received both vaccinations in the different study groups and human convalescent sera (HCS) samples (Hos hospitalized, Out outpatients) measured by microneutralization. Bars show median values per group at each study timepoint (whiskers show IQR) and individual GMT values for each sample shown as diamonds. Numbers show median MN50 values at day 43 for each group, and in the convalescent sera